Rx-360 Summary of Q&A on WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce
Rx-360 has published a Summary of Q&A on WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce.
WHO has issued a draft Q&A document on their Certification Scheme for Finished Products Moving in International Commerce. The WHO Certification Scheme for finished pharmaceutical products is an international voluntary agreement to provide assurance to countries participating in the Scheme, about the quality of pharmaceutical products moving in international commerce.
The primary document of the Scheme was the Certificate of Pharmaceutical Product (CPP). The WHO Expert Committee on Specifications for Pharmaceutical Preparations, during its forty-third meeting, recommended that the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce should be reviewed in light of the changing environment, including the rapid globalization of the pharmaceutical manufacturing sector coupled with changes in the make-up of both the regulators and the groups involved in procurement. In addition, at the time it was also requested that a questions and answers (Q&A) document be developed as an interim measure.
This draft document is an updated collection of questions and answers related to the WHO Certification Scheme on the Quality of Pharmaceutical Products moving in International Commerce and specifically to the CPP. Questions have been grouped into five separate categories for easier reference.
To view or download the WHO working document can be viewed, click here.
To view or download the Rx-360 Summary, click here.
Related News
-
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News US FDA grants priority review for Eisai and Biogen's Alzheimer's drug
Decision by US drug regulator on lecanemab expected by early next year -
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPHI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPHI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance